Semax raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-09 and is reviewed periodically as new material appears.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
=== Regional === Central German football championship (I) Winners (11): 1903, 1904, 1906, 1907, 1910, 1911, 1913, 1918, 1920, 1925, 1927 Runners-up: 1914, 1923, 1930 Gauliga Sachsen (I) Runners-up: 1933–34, 1938–39 Regionalliga Nordost (IV) Winners: 2019–20, 2024–25, 2025–26 NOFV-Oberliga Süd (V) Winners: 2015–16 Runners-up: 1998–99, 1999–2000, 2000–01 Sachsenliga (VI) Winners: 1998 Saxony Cup Winners: 1995–96, 2020–21, 2022–23, 2024–25 Runners-up: 2016–17
=== Free content work === This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 IGO (license statement/permission). Text taken from In brief, The State of World Fisheries and Aquaculture, 2018, FAO, FAO. This article incorporates text from a free content work. Licensed under Cc BY-SA 3.0 IGO (license statement/permission). Text taken from Drowning in Plastics – Marine Litter and Plastic Waste Vital Graphics, United Nations Environment Programme.
The Poles supplied almost 100,000 men for the invasion force, but against their expectations, Napoleon avoided any concessions to Poland, having in mind further negotiations with Russia. The Grande Armée marched through Russia, winning some relatively minor engagements and the major Battle of Smolensk on 16–18 August. In the same days, part of the French Army led by Marshal Nicolas Oudinot was stopped in the Battle of Polotsk by the right wing of the Russian Army, under command of General Peter Wittgenstein. This prevented the French march on the Russian capital, Saint Petersburg; the fate of the invasion was decided in Moscow, where Napoleon led his forces in person.
Neuropsychological tests including cognitive tests such as the mini–mental state examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the Mini-Cog are widely used to aid in diagnosis of the cognitive impairments in AD. These tests may not always be accurate, as they lack sensitivity to mild cognitive impairment, and can be biased by language or attention problems; more comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease. Further neurological examinations are crucial in the differential diagnosis of Alzheimer's disease and other diseases. Interviews with family members are used in assessment, and caregivers can supply important information on daily living abilities and on the decrease in the person's mental function. A caregiver's viewpoint is particularly important, since a person with Alzheimer's disease is commonly unaware of their deficits. Many times, families have difficulties in the detection of initial dementia symptoms and may not communicate accurate information to a physician. Supplemental testing can rule out other potentially treatable diagnoses and help avoid misdiagnoses. Common supplemental tests include blood tests, thyroid function tests, as well as tests to assess vitamin B12 levels, rule out neurosyphilis and rule out metabolic problems (including tests for kidney function, electrolyte levels and for diabetes). MRI or CT scans might also be used to rule out other potential causes of the symptoms – including tumors or strokes.
== Management == Nitroglycerin can be used immediately to dilate the venous system and reduce the circulating blood volume, therefore reducing the work and oxygen demand of the heart. In addition, nitroglycerin causes peripheral venous and artery dilation reducing cardiac preload and afterload. These reductions allow for decreased stress on the heart and therefore lower the oxygen demand of the heart's muscle cells. Antiplatelet drugs such as aspirin and clopidogrel can reduce platelet aggregation at the unstable atherosclerotic plaque, as well as combining these with an anticoagulant such as a low molecular weight heparin, can reduce clot formation.
Sources: en.wikipedia.org
== History == The sweetening properties of Synsepalum dulcificum berries were first noted by des Marchais during expeditions to West Africa in the 18th century. The term miraculin derived from experiments to isolate and purify the active glycoprotein that gave the berries their sweetening effects, results that were published simultaneously by Japanese and Dutch scientists working independently in the 1960s (the Dutch team called the glycoprotein mieraculin). The word miraculin was in common use by the mid-1970s.
==== 1998 congressional campaign ==== In 1998, Yates opted to forgo reelection, and Pritzker ran in the Democratic primary to succeed him, reconstituting his campaign committee in April 1997. Also running in the primary were state representative Jan Schakowsky and state senator Howard W. Carroll. The district covered the northern lakefront of Chicago, as well as the suburbs of Evanston and Skokie. It had a large Jewish electorate and had long been regarded as the "Jewish seat" in Illinois's congressional delegation. Yates was Jewish, as were all three Democratic contenders to succeed him. The district had been described as being among the most liberal in the country. Journalist James Ylisela Jr. observed that Pritzker, Schakowsky, and Carroll largely all ran on platforms aligned with the "liberal Democratic Party agenda" that Yates had championed. But the Chicago Tribune wrote that Pritzker and Carroll ran on more moderate platforms than Schakowsky, and therefore potentially wound up competing with each other for many of the same voters. At the time, the election was one of the most expensive congressional primaries in U.S. history, and Pritzker spent nearly $1 million of his own money on his campaign. This included $500,000 on television ads in the Chicago market. He finished third among five candidates in the Democratic primary, with 20.5% of the vote to Schakowsky's 45.1% and Carroll's 34.4%. Schakowsky went on to represent the district for 28 years, retiring after the 2026 election.
As part of Operation Unified Response, the 2d BCT, on rotation as the division's Global Response Force, was alerted and deployed forces to Haiti later that same day for the mission to provide humanitarian assistance following the devastating earthquake in Haiti. Paratroopers distributed water and food during the 2010 Haiti earthquake relief. Just two months following redeployment from Haiti in 2010, elements of 2d BCT (Red Falcons) deployed to Afghanistan in support of Operation Enduring Freedom to serve as trainers for the Afghan National Security Forces. In October 2011, the Division Headquarters returned to Afghanistan, where they relieved the 10th Mountain Division as the Headquarters of Regional Command-South. In February 2012, 4th BCT deployed to Kandahar province. Taliban commander Mullah Dadullah, formed an overwhelming force in Kandahar. Zhari district in southern Kandahar is where Dadullah was recruiting a high number of jihadists. 4th BCT of the 82nd held the 5-month siege from March 2012 to the end of July, witnessing some of the most intense combat since the initial deployments since 2001, 4th BCT inflicted massive casualties among the Taliban. Performing with an almost perfect strategic plan, 4th BCT drove Dadullah and his men out of Kandahar to the Northeastern province of Kunar, where Dadullah was killed by airstrikes. As of April 2012, the 1st BCT was deployed to Afghanistan, operating in Ghazni Province, Regional Command-East.
One employee stated that "he had been told by a close friend of one of the MIC operators that water had entered through a tube that had been connected to the tank." This had been allegedly discovered by the other MIC operators who then tried to open and close valves to prevent the release. The Little report argues that this evidence demonstrates that the following chronology took place:
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.